
## Alessio Biagioni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5360063/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction. Oncology Research, 2022, 29, 33-46.	0.6	2
2	Editorial: Redox Potential and Metabolic Behavior in Gastrointestinal Cancers. Frontiers in Oncology, 2022, 12, 882237.	1.3	0
3	Immunohistochemistry for VM Markers. Methods in Molecular Biology, 2022, , 141-152.	0.4	2
4	Th17 lymphocyteâ€dependent degradation of joint cartilage by synovial fibroblasts in a humanized mouse model of arthritis and reversal by secukinumab. European Journal of Immunology, 2021, 51, 220-230.	1.6	8
5	uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells. Cellular and Molecular Life Sciences, 2021, 78, 3057-3072.	2.4	38
6	Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNPâ€Enriched Endothelial Colony Forming Cells on Melanoma. Advanced Science, 2021, 8, 2001175.	5.6	12
7	Theranostic Nanoparticles: Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNPâ€Enriched Endothelial Colony Forming Cells on Melanoma (Adv. Sci. 4/2021). Advanced Science, 2021, 8, 2170017.	5.6	0
8	CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines. Frontiers in Oncology, 2021, 11, 663225.	1.3	11
9	Small nucleolar <scp>RNA</scp> host genes promoting epithelial–mesenchymal transition lead cancer progression and metastasis. IUBMB Life, 2021, 73, 825-842.	1.5	14
10	Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line. International Journal of Molecular Sciences, 2021, 22, 7698.	1.8	11
11	Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential. Cancers, 2021, 13, 4372.	1.7	4
12	uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells. Oncology Research, 2021, 28, 873-884.	0.6	10
13	Editing SOX Genes by CRISPR-Cas: Current Insights and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 11321.	1.8	6
14	5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer. Biology, 2020, 9, 265.	1.3	5
15	The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells. Journal of Molecular Medicine, 2020, 98, 1431-1446.	1.7	58
16	Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma. Cancers, 2020, 12, 1771.	1.7	6
17	uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines. Cells, 2020, 9, 308.	1.8	15
18	microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis, 2020, 9, 22.	2.1	30

ALESSIO BIAGIONI

#	Article	IF	CITATIONS
19	EMT signaling: potential contribution of CRISPR/Cas gene editing. Cellular and Molecular Life Sciences, 2020, 77, 2701-2722.	2.4	22
20	MAP Kinases Pathways in Gastric Cancer. International Journal of Molecular Sciences, 2020, 21, 2893.	1.8	40
21	Update on gastric cancer treatments and gene therapies. Cancer and Metastasis Reviews, 2019, 38, 537-548.	2.7	127
22	Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. Cancer Letters, 2019, 446, 25-37.	3.2	28
23	EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells. EBioMedicine, 2019, 39, 194-206.	2.7	31
24	Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis. Journal of Experimental and Clinical Cancer Research, 2018, 37, 74.	3.5	21
25	SOX2 as a novel contributor of oxidative metabolism in melanoma cells. Cell Communication and Signaling, 2018, 16, 87.	2.7	27
26	Delivery systems of CRISPR/Cas9-based cancer gene therapy. Journal of Biological Engineering, 2018, 12, 33.	2.0	35
27	Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. Journal of Molecular Medicine, 2017, 95, 1341-1353.	1.7	76
28	Type II CRISPR/Cas9 approach in the oncological therapy. Journal of Experimental and Clinical Cancer Research, 2017, 36, 80.	3.5	17
29	uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells. International Journal of Cancer, 2017, 141, 1190-1200.	2.3	40
30	Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells. Molecular and Cellular Biochemistry, 2017, 424, 99-110.	1.4	10
31	Roles of different IRES-dependent FGF2 isoforms in the acquisition of the major aggressive features of human metastatic melanoma. Journal of Molecular Medicine, 2017, 95, 97-108.	1.7	9
32	Identification of Novel Human Breast Carcinoma (MDA-MB-231) Cell Growth Modulators from a Carbohydrate-Based Diversity Oriented Synthesis Library. Molecules, 2016, 21, 1405.	1.7	2
33	Endothelial Progenitor Cells as Shuttle of Anticancer Agents. Human Gene Therapy, 2016, 27, 784-791.	1.4	18
34	Tumor-tropic endothelial colony forming cells (ECFCs) loaded with near-infrared sensitive Au nanoparticles: A "cellular stove―approach to the photoablation of melanoma. Oncotarget, 2016, 7, 39846-39860.	0.8	20
35	Abstract 5063: The receptor for urokinase-plasminogen activator controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. , 2016, , .		0
36	Differential u PAR recruitment in caveolarâ€lipid rafts by GM 1 and GM 3 gangliosides regulates endothelial progenitor cells angiogenesis. Journal of Cellular and Molecular Medicine, 2015, 19, 113-123.	1.6	19

ALESSIO BIAGIONI

#	Article	IF	CITATIONS
37	Inhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells. Journal of Molecular Medicine, 2015, 93, 783-794.	1.7	39
38	Endothelial Progenitor Cells in Sprouting Angiogenesis: Proteases Pave the Way. Current Molecular Medicine, 2015, 15, 606-620.	0.6	39
39	Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget, 2014, 5, 3711-3727.	0.8	37
40	The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget, 2014, 5, 1538-1553.	0.8	42